SNO 2020: Nivolumab + Hypofractionated Reradiation + Bevacizumab Shows Promise in Recurrent MGMT-Methylated GBM
Patients have tolerated the treatment well.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.